As shown in panels a–i of Figure 5, to explore the differences in the association between radiomics features and TP53 mutation status across different tumor types, we conducted feature differential analyses separately in patients with cervical cancer, ovarian cancer, and endometrial cancer. The gene discussed is TP53; the disease is cervical cancer.